The Probiotic Therapy for the Reversal of Bacterial Vaginosis in Pregnancy trial (ProVIP) is a pilot study that seeks to determine whether an oral lactobacilli preparation, compared to placebo, administered to pregnant women diagnosed with bacterial vaginosis (BV) or intermediate flora will reverse the condition, leading to a decrease in the inflammatory mediators involved in the cascade of infection/inflammation-mediated preterm birth. The results will potentially serve as the basis for a multi-centre, randomized clinical trial to determine the efficacy of this treatment in preventing preterm birth among women diagnosed with BV.

The sample size for ProVIP is 86 pregnant women (43 per group), to be recruited from 2 centres in Toronto.

For more information, please email Mary-Jean Martin at

Click here for ProVIP news.